



FG Onco Lapatinib

Pharmacogenetics of
lapatinib treatment

SYNLAB 
SOLUTIONS IN DIAGNOSTICS

www.synlab-sd.com



Why undergoing this examination?

Lapatinib is a medication used in the chemotherapy of breast cancer and other solid tumors. It belongs to the group of kinase inhibitors, which act by blocking the action of the abnormal protein that signals tumor cells to multiply. Several scientific studies show that different HLA (human leukocyte antigen) polymorphisms within the major histocompatibility complex (MHC) are strongly associated with the hepatotoxicity of lapatinib treatment. This hepatotoxicity can appear within a few days or several months after the start of treatment.

What is the exam?

The **FG Onco Lapatinib** genetic profile evaluates whether the patient carries the HLA alleles DQA102:01 and DRB107:01. The purpose of the test is to identify those patients with an increased risk of developing serious side effects, especially hepatotoxicity, during lapatinib treatment.

For whom is it indicated?

- Patients undergoing pharmacological treatment that does not yield expected results;
- Patients experiencing drug-related side effects.

Technology

Next-generation sequencing (NGS).

Advantages

SYNLAB GROUP

Guaranteed by the experience of the absolute European leader in laboratory diagnostics.

COMPLETE

Detailed report, where the results will suggest individualized courses of action, aiding in prognosis for greater treatment efficacy and a significant reduction in adverse reactions.

Extra Information

DOCUMENTATION - Available on the SYNLAB Direct for clients

- Informed Consent;
- Clinical Questionnaire;
- Medical prescription.

PREPARATION

- Fasting is not necessary for the exam.



Delivery Time

12 business days



Sample Type

5 mL of whole blood in EDTA